Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 20 trials

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

16Total
Not Applicable (5)
Early P 1 (2)
P 1 (8)
P 4 (1)

Trial Status

Recruiting10
Not Yet Recruiting5
Active Not Recruiting2
Withdrawn2
Unknown1

Clinical Trials (20)

Showing 20 of 20 trials
NCT07713511Not Yet Recruiting

INfections in Patients Treated With CAR-T

NCT06703216Phase 1Not Yet Recruiting

Pre-emptive Anakinra for Cytokine Event Reduction

NCT06575712Not ApplicableRecruiting

Coping Skills Training for Symptom Management and Daily Steps (Step Up)

NCT06508346Withdrawn

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV

NCT06842589Phase 1Withdrawn

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS

NCT05858684Early Phase 1RecruitingPrimary

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

NCT06802406Not ApplicableRecruiting

Nutrition OUtReach In Systems of Healthcare

NCT06222853Phase 1Active Not Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

NCT07296120Phase 4Not Yet RecruitingPrimary

RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients

NCT07269587Active Not Recruiting

A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19

NCT07246304Early Phase 1Recruiting

TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

NCT07198867Phase 1Recruiting

A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

NCT06553898Phase 1Recruiting

Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS

NCT07120633Not ApplicableRecruiting

Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL

NCT06935136Not ApplicableNot Yet RecruitingPrimary

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma

NCT06554951RecruitingPrimary

Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapies

NCT06647329Phase 1Not Yet RecruitingPrimary

CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors

NCT06196294Phase 1Recruiting

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

NCT05779917Phase 1Recruiting

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

NCT04280133Not ApplicableUnknown

CAR T-CELL Therapy Educational Video Trial

Showing all 20 trials

Research Network

Activity Timeline